The demand for nucleic acid therapeutics (NATs) is rapidly altering the therapeutic landscape across a wide range of diseases. Recent industry data highlig...
Regulatory submission filed to initiate a Phase 2a trial of its drug candidate, PTI5803 in patients with focal cortical dysplasia (FCD), a rare and sev...
In this exclusive BioPharma Boardroom interaction, Thierry Van Nieuwenhove, CEO of Quotient Sciences, explores why nearly 90% of drug candidates fail and w...
Efficient production of Adeno-Associated Virus (AAV) vectors at scale for in vivo gene therapies remains a key bottleneck for broad patient access an...
BioOra Limited ("BioOra"), a commercial-stage cell therapy company advancing CAR-T therapies for cancer patients, and Octane Biotech Inc., an Octane Medi...
EPO Greenlights Claims Covering Preventative use of therapy targeting 5-HT4 Pathway and Expands Silo Pharma IP Portfolio Silo Pharma, Inc. (Nasdaq: SILO...
A pivotal step in PharmaEssentia's dual-site U.S.-Taiwan manufacturing strategy, with 2027 operations in sight PharmaEssentia Corporation (TWS...
From a basement-born idea to a publicly traded biotech advancing late-stage clinical trials, Lew Bender’s journey reflects both scientific persistenc...
Thermo Fisher Scientific Inc., the world leader in serving science, announced a next-generation, integrated cell line development platform that ena...
Lilly to gain ownership of Centessa's OX2R agonist pipeline designed to improve outcomes across sleep-wake disorders Centessa’s OX2R agonist pip...
Adds 60,000 liters of drug substance capacity, bringing the total to 845,000 liters Marks Samsung Biologics’ geographical diversific...
4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces a significant expansio...
Company has already submitted proposed confirmatory trial for FDA review, as required under accelerated approval pathway Company plans to submit...
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation c...
© 2026 Biopharma Boardroom. All Rights Reserved.
